Ticagrelor was similarly more effective than clopidogrel in reducing rates of the primary endpoint in women 11.2 vs. 13.2 % [ adjusted HR : 0.88 ( 0.74-1 .06 ) ] and men 9.4 vs. 11.1 % [ adjusted HR : 0.86 ( 0.76-0 .97 ) ] ( interaction P-value 0.78 ) , all-cause death in women 5.8 vs. 6.8 % [ adjusted HR : 0.90 ( 0.69-1 .16 ) ] and men 4.0 vs. 5.7 % [ adjusted HR : 0.80 ( 0.67-0 .96 ) ] ( interaction P-value 0.49 ) , and definite stent thrombosis in women 1.2 vs. 1.4 % [ adjusted HR : 0.71 ( 0.36-1 .38 ) ] and men 1.4 vs. 2.1 % [ adjusted HR : 0.63 ( 0.45-0 .89 ) ] ( interaction P-value 0.78 ) .